Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MP0533

Monoclonal antibody · Kills target cells, directed at Interleukin-3 receptor subunit alpha (IL3RA) · developed by Molecular Partners

Phase 1 Most advanced trial (none active)
MOLN Developer
1 Registered trials

What is MP0533?

MP0533 is an agent administered by intravenous infusion that is studied in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
Interleukin-3 receptor subunit alpha (IL3RA)
Mechanism
Kills target cells, directed at Interleukin-3 receptor subunit alpha (IL3RA)
Pathways
interleukin-3 signaling
Therapy area
Oncology
Developer
Molecular Partners AG (MOLN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05673057 Phase 1 Leukemia Completed MOLN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AcuteLeukemiaMyeloidNewly Diagnosed

Other drugs acting on IL3RA

More from Molecular Partners

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the MOLN page.

Follow MOLN, the company behind MP0533

See MOLN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MOLN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.